Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: Progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins
Abstract
Identifying molecular targets for eliciting broadly virus-neutralizing antibodies is one of the key steps toward development of vaccines against emerging viral pathogens. Owing to genomic and somatic diversities among viral species, identifying protein targets for broad-spectrum virus neutralization is highly challenging even for the same virus, such as HIV-1. However, viruses rely on host glycosylation machineries to synthesize and express glycans and, thereby, may display common carbohydrate moieties. Thus, exploring glycan-binding profiles of broad-spectrum virus-neutralizing agents may provide key information to uncover the carbohydrate-based virus-neutralizing epitopes. In this study, we characterized two broadly HIV-neutralizing agents, human monoclonal antibody 2G12 and Galanthus nivalis lectin (GNA), for their viral targeting activities. Although these agents were known to be specific for oligomannosyl antigens, they differ strikingly in virus-binding activities. The former is HIV-1 specific; the latter is broadly reactive and is able to neutralize viruses of distinct phylogenetic origins, such as HIV-1, severe acute respiratory syndrome coronavirus (SARS-CoV), and human cytomegalovirus (HCMV). In carbohydrate microarray analyses, we explored the molecular basis underlying the striking differences in the spectrum of anti-virus activities of the two probes. Unlike 2G12, which is strictly specific for the high-density Man<inf>9</inf>GlcNAc<inf>2</inf>Asn (Man9)-clusters, GNA recognizes a number of N-glycan cryptic sugar moieties. These include not only the known oligomannosyl antigens but also previously unrecognized tri-antennary or multi-valent GlcNAc-terminating N-glycan epitopes (Tri/m-Gn). These findings highlight the potential of N-glycan cryptic sugar moieties as conserved targets for broad-spectrum virus neutralization and suggest the GNA-model of glycan-binding warrants focused investigation. Copyright 2015 by the authors.Sponsors
National Natural Science Foundation of China, NSFC: 81270665; National Institutes of Health, NIH: R56AI108388Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928610763&doi=10.3390%2fmolecules20034610&partnerID=40&md5=97eef9985af87285f58be208236b88c2; http://hdl.handle.net/10713/12406ae974a485f413a2113503eed53cd6c53
10.3390/molecules20034610
Scopus Count
Collections
Related articles
- N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
- Authors: Gray ES, Moore PL, Pantophlet RA, Morris L
- Issue date: 2007 Oct
- Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea mays strongly determine their eventual anti-HIV activity.
- Authors: Hoorelbeke B, Van Damme EJ, Rougé P, Schols D, Van Laethem K, Fouquaert E, Balzarini J
- Issue date: 2011 Feb 11
- An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.
- Authors: Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, Mboudjeka I, Lee FH, Montefiori D, Smith DF, Doms RW, Geng Y
- Issue date: 2008 Jul
- Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.
- Authors: Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien JP, Menis S, Wickramasinghe L, Seaman MS, Schief WR, Wilson IA, Poignard P, Burton DR
- Issue date: 2014 May 14
- Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
- Authors: Sui J, Deming M, Rockx B, Liddington RC, Zhu QK, Baric RS, Marasco WA
- Issue date: 2014 Dec